{"id":474949,"date":"2025-05-30T00:00:00","date_gmt":"2025-05-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0177-biopharma-sarcopenia-epidemiology-epidemiology-sarcopenia-mature-markets\/"},"modified":"2026-05-02T23:16:54","modified_gmt":"2026-05-02T23:16:54","slug":"epidim0177-biopharma-sarcopenia-epidemiology-epidemiology-sarcopenia-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0177-biopharma-sarcopenia-epidemiology-epidemiology-sarcopenia-mature-markets\/","title":{"rendered":"Sarcopenia &#8211; Epidemiology &#8211; Epidemiology &#8211; Sarcopenia &#8211; Mature markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of sarcopenia comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the total prevalence of sarcopenia for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.<\/p>\n<p>Clarivate Epidemiology\u2019s sarcopenia forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people with sarcopenia per year?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of sarcopenia over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <span class=\"abbreviation-guard\">MS <\/span>Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology forecasts the following sarcopenia populations:<\/p>\n<ul class=\"round-bullets\">\n<li>Total prevalent cases of European Working Group on Sarcopenia in Older People 2 (<abbr data-abbreviation-entity=\"10744\" title=\"European Working Group on Sarcopenia in Older People\">EWGSOP<\/abbr>2) \/ Asian Working Group for Sarcopenia 2 (<abbr data-abbreviation-entity=\"10745\" title=\"Asian Working Group for Sarcopenia\">AWGS<\/abbr>2)<sup>1<\/sup> sarcopenia.<\/li>\n<li>Total prevalent cases of severe <abbr data-abbreviation-entity=\"10744\" title=\"European Working Group on Sarcopenia in Older People\">EWGSOP<\/abbr>2\/<abbr data-abbreviation-entity=\"10745\" title=\"Asian Working Group for Sarcopenia\">AWGS<\/abbr>2 sarcopenia.<\/li>\n<li>Total prevalent cases of non-severe <abbr data-abbreviation-entity=\"10744\" title=\"European Working Group on Sarcopenia in Older People\">EWGSOP<\/abbr>2\/<abbr data-abbreviation-entity=\"10745\" title=\"Asian Working Group for Sarcopenia\">AWGS<\/abbr>2 sarcopenia.<\/li>\n<li>Total prevalent cases of <abbr data-abbreviation-entity=\"10744\" title=\"European Working Group on Sarcopenia in Older People\">EWGSOP<\/abbr>1\/<abbr data-abbreviation-entity=\"10745\" title=\"Asian Working Group for Sarcopenia\">AWGS<\/abbr>1 sarcopenia.<\/li>\n<\/ul>\n<p><sup>1<\/sup>The <abbr data-abbreviation-entity=\"10744\" title=\"European Working Group on Sarcopenia in Older People\">EWGSOP<\/abbr>2 (Cruz-Jentoft <span class=\"abbreviation-guard\">AJ<\/span>, 2019) and <abbr data-abbreviation-entity=\"10745\" title=\"Asian Working Group for Sarcopenia\">AWGS<\/abbr>2 (Chen <span class=\"abbreviation-guard\">LK<\/span>, 2020) diagnostic criteria are based on similar frameworks but focus on European and Asian populations, respectively; <abbr data-abbreviation-entity=\"10744\" title=\"European Working Group on Sarcopenia in Older People\">EWGSOP<\/abbr>1 (Cruz-Jentoft <span class=\"abbreviation-guard\">AJ<\/span>, 2010) and <abbr data-abbreviation-entity=\"10745\" title=\"Asian Working Group for Sarcopenia\">AWGS<\/abbr>1 (Chen <span class=\"abbreviation-guard\">LK<\/span>, 2014) are their previous versions.<\/p>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-474949","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-epidemiology","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/474949","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/474949\/revisions"}],"predecessor-version":[{"id":475292,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/474949\/revisions\/475292"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=474949"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}